MAVERICK Trial Results Favored MRI Over Radiation
A study presented on Sept. 12, 2026, found MRI surveillance reduced cognitive decline in lung cancer patients.
Updated on Oct. 8, 2026 in Cancer
Live Poll
Do you trust non-invasive monitoring over preventative radiation to maintain your memory and long-term health?
Results from the phase 3 MAVERICK trial, presented on Sept. 12, 2026, showed that MRI surveillance alone led to less cognitive decline than prophylactic cranial irradiation. The study of 304 patients with small cell lung cancer suggests a shift in post-treatment care.
Why it matters
Prophylactic cranial irradiation is traditionally used to prevent cancer from spreading to the brain, but it carries risks of neurological side effects. This trial offers evidence that monitoring via MRI may preserve patient quality of life without compromising survival.
The phase 3 trial enrolled 304 participants, with a median follow-up period of 22 months. Brain metastases occurred more frequently in the MRI-only group, despite the lower risk of overall cognitive decline or death.
The players
University of Colorado School of Medicine
This institution is a leading academic medical center and provided the lead researcher for the presentation of the MAVERICK trial.
IASLC
The International Association for the Study of Lung Cancer is a global organization dedicated to the study and treatment of lung cancer.
The details
Researchers performed brain MRIs every three months in the first year and every six months in the second year for those in the surveillance group. While prophylactic cranial irradiation is a standard preventative measure, this study indicates no clear difference in overall survival between the two treatment methods.
Timeline
Sept. 12, 2026: Trial results were presented at the IASLC World Conference.
The Big Picture
This report extends the findings established in the SWOG S1827 MAVERICK trial clinical registry by providing the latest outcomes regarding cognitive decline.
Patients may see changes in post-treatment monitoring protocols as clinicians weigh the risk of cognitive side effects against potential brain metastases. This data provides doctors and patients with more evidence to personalize follow-up care plans.
The takeaway
The study demonstrates that reducing aggressive preventative radiation can significantly benefit a patient's cognitive health. Families and patients should discuss the trade-offs between routine MRI monitoring and prophylactic radiation with their oncology team.
Further reading
Find more clinical updates in the Cancer section.
More information
Read the full study details on the SWOG S1827 MAVERICK trial clinical registry.
Source note: This article includes information reported by Curetoday.
Live Poll
Do you trust non-invasive monitoring over preventative radiation to maintain your memory and long-term health?
